Introduction
Although levetiracetam (LEV) has been available since 1999 as an antiepileptic drug, its mechanism of action has not been conclusively elucidated. There is some evidence LEV can affect a variety of ligand-and voltage-gated neuronal channels, but the evidence for this is not compelling. However, biochemical data quite convincingly demonstrate that LEV specifically binds to the presynaptic vesicle protein SV2A. 1 Very recent data even correlate LEV's efficacy as an antiepileptic with the presence of the SV2A protein: mice heterozygous for an SV2A knockout were less sensitive to the antiepileptic effect of LEV in various experimental epilepsy models. 2 To date, however, there has been a dearth of neurophysiological evidence consistent with a presynaptic locus for LEV's antiepileptic effect. We previously demonstrated a very noticeable effect of LEV on synaptic transmission and presynaptic vesicle release. These results utilized data obtained from separate populations of hippocampal slices incubated for different periods of time in the presence or absence of LEV, and its inactive isomer UCB L060. 3 These experiments did not allow us to determine the latency of onset of LEV action, nor did they allow us to continually examine physiological properties in the same brain slices.
Because the accurate determination of LEV onset is an extremely important issue for clinical use, we serially assessed synaptic physiology in the same slices in order to more precisely determine when the LEV's effect manifests and to try to verify our earlier physiological observations.
Methods

Animals and hippocampal slice preparation
Four-to six-week-old male Sprague-Dawley rats were used for all experiments. Care and use of animals conformed to a protocol approved by the University of Minnesota Institutional Animal Care and Use Committee. The rats were anesthetized with halothane and rapidly decapitated. The brains were removed and briefly immersed in ice-cold artificial cerebrospinal fluid (ACSF) containing (mM): 124 NaCl, 5 KCl, 2 CaCl 2 , 2 MgSO 4 , 1.25 NaH2PO 4 , 22 NaHCO 3 , and 10 glucose, and continuously bubbled with a 95% O 2 / 5% CO 2 gas mixture. They were then placed on their dorsal surface on ACSF-dampened filter paper. The cerebellum and brain stem were removed with a scalpel, and the portion of the brain anterior to the optic chiasm was removed with one coronal cut. The flat frontal surface was then rotated down, and the ventral surface was placed against an agarose block in a vibratome pan (Pelco, St. Louis, MO, USA). The pan was filled with oxygenated ice-cold ACSF, and the vibratome well was filled with ice water. We cut 500 mM We recently reported that rodent hippocampal slices incubated with levetiracetam for 3 h had altered responses to repetitive stimulation and reduced neurotransmitter release. However, our experiments failed to determine the actual time course of diminished transmission in individual slices followed over time. We have now been able to record from the same slices for up to 3 h to determine the latency of the levetiracetam effect after the onset of exposure. Within 30 min of levetiracetam exposure, the later field potentials of a burst were reduced. Between 60 and 180 min the relative size of later field potentials remained stable. Similar time-dependent reductions were not seen in control slices or in slices exposed to the inactive levetiracetam isomer UCB L060. These new results establish a clear time dependence of the levetiracetam effect, even in vitro, and are best explained by levetiracetam acting within neurons to alter synaptic vesicle release.
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transverse slices using the highest blade vibration setting and an excursion speed that allowed the blade to pass in 20-30 s. The hemispheres of each slice were separated and incubated in a submerged, oxygenated holding chamber (BSC-PC, Warner Instruments, Hamden, CT, USA) at 25 8C for 1-3 h before transfer to a recording chamber.
Electrophysiology experiments
Electrophysiological recordings were made in a submerged chamber (RC-26G, Warner Instruments) perfused with oxygenated control ACSF or ACSF containing LEV or UCB L060. Perfusion rate was 2 ml min À1 and the inflow was heated to 33 8C (SH-27B, Warner). All chemicals mentioned below were dissolved in ACSF. Our recording microelectrodes were made from 1. . At the start of experiments, an input-output curve was established for the amplitude of the field EPSP (fEPSP), from which half-maximal stimulation intensity was determined. This stimulation strength was used for the remainder of the recording session and varied by approximately twofold from slice to slice. Field potentials from the dendritic layer of CA1 were fed into a conventional DC amplifier (Axoclamp 2A; Axon Instruments, Union City, CA, USA), digitized at 1 kHz, and stored on a personal computer using a commercially available A/D converter and software (Digidata 1200 and pClamp 9; Axon Instruments). The magnitude of individual field potentials was measured between onset and peak negative deflection (Fig. 1A) . To determine the effects of LEV and UCB L060, we delivered three trains of 20 stimuli (40 Hz), separated by 1 min, and averaged the three. We repeated this sequence every 30 min for 3 h and calculated the ratio of the ''n''th to the first postsynaptic potential (EPSP n /EPSP 1 ). Normalizing the field potentials in this way allowed us to compare responses across different slices and experimental conditions. We limited the number of repetitive stimulations to avoid inducing long term potentiation.
Chemicals
All reagents were purchased from Sigma (St. Louis, MO) except for 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), which was purchased from Tocris Bioscience (Ellisville, MO, USA) and LEV and UCB L060 which were both supplied by UCB SA, Belgium. 
Results
Effect of LEV on repetitive stimulation
In the presence of LEV (100 mM), there was a clear decrement in the size of repetitive field potentials over the interval from 30 min to 3 h (Fig. 1A) . In the actual raw traces of the 0.5 s 40 Hz bursts, this decrement was apparent by 30 min, and in the normalized field potentials became more evident during later responses within the bursts (Fig. 2A) (Figs. 1B and C and 2B and C) . This makes it highly unlikely that the changes in field potentials observed over time in LEV could be attributed to the duration of the experiment.
When we compared the amplitudes of the normalized field potentials over time in the LEV groups to the UCB L060 and control groups, we also saw significant differences that were more apparent at the later EPSPs in the bursts (Fig. 3) . At time 0, as expected neither the second nor twentieth normalized EPSP differed between the three groups. At 180 min, the normalized amplitudes of the second and third EPSPs were also not significantly different among LEV, UCB L060, and control. However, the normalized amplitude of the fourth EPSP and beyond in the LEV group, was significantly reduced compared to UCB L060 and control.
Alternative explanations for LEV's effect
In addition, we were concerned that there might be a cumulative effect of LEV on synaptic transmission that could account for the reduction in normalized field potentials during repetitive stimulation. We, therefore, plotted the absolute value of the initial field potentials in control slices and slices exposed to LEV and UCB L060 (Fig. 4A) . There was no progressive decline in initial field potential amplitudes in any of the three experimental conditions. With LEV exposure, there was actually a small, but statistically insignificant, increase in the initial field potentials over the 3 h observation period. Our observations with LEV during Fig. 3 . Time-and stimulus-dependent effect of LEV compared to UCB L060 and control. At 0 min, the amplitude of the second and twentieth normalized EPSP in LEV (n = 6) did not significantly differ from the UCB L060 (n = 6) and control groups (n = 6) (a, p > 0.05 by Student-Newman-Keuls). At 180 min, the amplitude of the second EPSP and third EPSP in LEV still did not significantly differ from UCB L060 and control (a, p > 0.05 by Student-Newman-Keuls). However, the fourth, tenth, and twentieth EPSPs in the LEV group become progressively smaller relative to the EPSPs in the UCB L060 and control groups (b, p < 0.05 by Student-Newman-Keuls). The inactive LEV isomer, UCB L060 had no effect on repetitive stimulation. In fact, as duration of exposure increased, the normalized field potential amplitudes in the stimulus train actually increased (n = 6 slices). (C) Control slices (n = 6) that were not exposed to any drug also maintained a consistent relative normalized field potential value. As with UCB L060, the normalized filed potentials slightly increased over time. In (A)-(C), error bars are standard deviations. They are only shown for times 0 and 180 because showing all error bars would produce excessive overlap.
repetitive stimulation cannot be explained by LEV simply depressing transmission.
The effect of LEV on transmission did not reach a steady-state until 1 h (Fig. 2A) . It is possible that a requirement for LEV to actually cross the neuronal cell membrane accounts for this long latency, but another possibility was that our perfusion configuration led to a delay in drug entry into the slice. In order to test this hypothesis, we looked at the kinetics of AMPA receptor block by the competitive AMPA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX). CNQX acts at the plasma membrane and does not require entry into the cell. At a subsaturating concentration of 1 mM, steady-state CNQX inhibition of field potentials was seen between 20 and 30 min (Fig. 4B ). This suggests that slice penetration alone cannot explain the delay in LEV inhibition of repetitive field potentials.
Discussion
Our new experiments support and extend prior results showing a stimulus-dependent effect of LEV on synaptic transmission and document a substantial delay before LEV exerts its full physiological effect even in a relatively simple in vitro physiological preparation. 3 We believe that this is the first set of in vitro physiology experiments to serially examine synaptic transmission in the same slices over a prolonged time course. Our previous slice observations documented that incubation of hippocampal slices in LEV for 3 h led to reduction of repetitive synaptic potentials and a concomitant decrease in vesicular release measured by FM1-43 destaining. We suggested that the failure of others to detect LEV's effect on transmission was probably due to an inadequate period of observation. The current results substantiate that explanation. Moreover, they show that looking only at single synaptic responses would probably have led to erroneous conclusions, because LEV's influence on transmission becomes more evident when serial responses are monitored. Our results document that LEV did not diminish the initial amplitude of the field potentials over time, confirming that the drug has a selective influence on repetitive synaptic transmission or burst discharges, which may account for its efficacy as an antiepileptic drug.
Our results are compatible with biochemical observations that LEV specifically and selectively binds a presynaptic vesicle protein, SV2A.
1 Since this protein resides within an intracellular compartment, LEV must also have to enter the neuron in order to influence synaptic transmission. CNQX, which acts on glutamate receptors on the neuronal surface and has a higher molecular weight (232 vs 170) and lower water solubility than LEV, exerts a more rapid effect than LEV, implying that the perfusion speed used in these experiments and slice penetration cannot account for the latency of the LEV's effect. Although the neurobiology SV2A has been extensively studied in mice lacking the protein, the precise function of the protein in normal transmission has still not been elucidated. [4] [5] [6] [7] Work on cultured neurons lacking SV2A initially suggested that the protein somehow increased the size of the readily releasable pool of neurotransmitter. 6 More recent tissue culture observations have confirmed an SV2A effect on synaptic release, but suggest it enhances vesicle sensitivity to calcium and synaptotagmin. 7 The observation by at least two groups that SV2A is not absolutely necessary for synaptic transmission may provide an interesting insight into LEV's relative lack of clinical neurotoxicity. 6, 7 Even complete binding of SV2A by high concentrations of LEV would not be expected to have an enormous effect on basal synaptic neurotransmission. Because SV2A's fundamental role in transmission is still undefined, it is difficult to propose a satisfactory explanation for LEV's modulation of repetitive stimulation. An cumulative effect of LEV on either vesicular binding of calcium or the rate of depletion of the readily releasable pool of vesicles would be compatible with our results, but we have no direct supporting evidence to date. The finding that SV2A is also a binding site for botulinum toxin is fascinating, but has not provided new insights into LEV's antiepileptic properties. 8, 9 Nonetheless, it supports the notion that interfering with SV2A will interfere with transmitter exocytosis. It would be helpful in the future to experimentally confirm that LEV exerts it effects within the synaptic terminal. This could be possible in cultured neurons, where fluorescent dyes could be used to compare the rates of vesicular release between control neurons and neurons directly injected with LEV through an intracellular pipette. Two in vivo lines of evidence provide additional support for a delayed onset of action of LEV, compatible with an intracellular site of action. First, some accounts of successful treatment of status epilepticus with intravenous levetiracetam report a much longer latency to seizure cessation than when status is aborted with benzodiazepines. 10, 11 Second, Epstein et al. found a substantial latency between peak serum levels of LEV and suppressive effects of LEV on transcranial magnetic stimulation thresholds in volunteers who had received a single loading dose of LEV. 12 Their result is best explained by LEV exerting its physiological effect in a body compartment removed from the extracellular space. Our results, taken together with these other reports, strongly support the unique properties of LEV. Moreover, the development of two new LEV analogs with higher SV2A affinity, brivaracetam and seletracetam, indicates that SV2A will remain a compelling target for new antiepileptic drug development. 13, 14 We believe that more rigorous neurobiological investigation of LEV will suggest even more imaginative strategies for designing new antiepileptic drugs.
